<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101811</url>
  </required_header>
  <id_info>
    <org_study_id>GhamraMH</org_study_id>
    <nct_id>NCT05101811</nct_id>
  </id_info>
  <brief_title>Vitamin D Levels in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Assessment of Serum Vitamin D Levels in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ghamra Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ghamra Military Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome is the commonest endocrinopathy among women of reproductive age.&#xD;
      Its worldwide prevalence has been estimated between5-10%.&#xD;
&#xD;
      Vitamin D, a fat-soluble vitamin, can be produced in two ways: by intestinal absorption and&#xD;
      endogenous synthesis from a precursor of 17-hydroxyl cholesterol on the skin with sufficient&#xD;
      exposure to ultraviolet sunlight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this work is assessment of the level of vitamin D in female have polycystic ovary&#xD;
      syndrome &amp; healthy female.and also make diagnostic criteria for patient who is in need for&#xD;
      supplementations with vitamin D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of vitamin D in Polycystic ovary syndrome</measure>
    <time_frame>1 year</time_frame>
    <description>vitamin D levels is assumed to be significantly decreased</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of vitamin D in fertile women</measure>
    <time_frame>1 year</time_frame>
    <description>vitamin D level is expected to be normal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Control women without polycystic ovary syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal fertile women without polycystic ovary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case women with polycystic ovary syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with polycystic ovary syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D Levels measurement using chemiluminescent assay</intervention_name>
    <description>Measurement of serum vitamin D levels</description>
    <arm_group_label>Case women with polycystic ovary syndrome</arm_group_label>
    <arm_group_label>Control women without polycystic ovary syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitamin D level assessment</intervention_name>
    <description>Using lIAISON DEVICE</description>
    <arm_group_label>Case women with polycystic ovary syndrome</arm_group_label>
    <arm_group_label>Control women without polycystic ovary syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Hyperandrogenism&#xD;
&#xD;
          -  Polycystic ovary syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Parathyroid disease&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Cushing syndrome&#xD;
&#xD;
          -  Congenital adrenal hyperplasia&#xD;
&#xD;
          -  Hyperprolactinemia&#xD;
&#xD;
          -  Renal, liver or chronic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Mohamed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghamra Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Misr Al Gadida Military hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ghamra Military Hospital</investigator_affiliation>
    <investigator_full_name>Osama Mansour Khalifa Mohamed</investigator_full_name>
    <investigator_title>Principal investigator,obstetrics and gynecologydepartment</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Summary and results</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
    <ipd_access_criteria>Al Azhar International Medical Journal</ipd_access_criteria>
    <ipd_url>https://aimj.journals.ekb.eg/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

